Rosiglitazone CV risk relative to metformin, sulfonylurea

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1161, 2007-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rosiglitazone/Metformin

By Wellington Keri  

Drugs, Vol. 65, Iss. 11, 2005-01 ,pp. : 1581-1592

Adis International

Access to resources Recommend Favorite

Adding rosiglitazone to metformin reaps benefits

By  

Inpharma, Vol. 1, Iss. 1233, 2000-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Rosiglitazone/metformin: Exophthalmos: case report

By  

Reactions Weekly, Vol. 1, Iss. 1153, 2007-01 ,pp. : 24-24

Adis International

Access to resources Recommend Favorite

A fixed combination of rosiglitazone plus metformin improves glycaemic control and cardiovascular risk factors in patients with type 2 diabetes mellitus (T2DM)

By  

Inpharma, Vol. 1, Iss. 1546, 2006-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Similar CV risks observed with rosiglitazone and pioglitazone

By  

Reactions Weekly, Vol. 1, Iss. 1318, 2010-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite